Evaluation of intrapericardial cisplatin (CIS) administration in cases with recurrent malignant pericardial effusion (MPE) in pts with lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 63s Year: 2003
Prognostic factors associated to survival in patients with malignant pleural effusion (MPE) undergoing talc poudrage pleurodesis (TPP) Source: International Congress 2016 – Malignant pleural disease: diagnosis and management Year: 2016
Thoracoscopic talc pleurodesis‘(TTP) safety and clinical efficacy in malignant pleural effusions (MPE) Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010
Thoracoscopic talc poudrage (TTP) in malignant (M) pleural effusion (PE): when to perform it? Source: International Congress 2019 – Interventional pulmonology: current pleural practice Year: 2019
Predictors of successful pleurodesis for patients with malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 493s Year: 2004
Tumour marker (TM) CA 19-9 in pleural fluid at patients with malignant and paramalignant pleural effusion (PE) Source: Eur Respir J 2001; 18: Suppl. 33, 387s Year: 2001
The role of thoracoscopy in the diagnosis of malignant pleural effusions (PE) Source: Eur Respir J 2002; 20: Suppl. 38, 438s Year: 2002
Efficacy of talc pleurodesis in patients with malignant pleural effusions Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011
Therapeutic local procedures: pleurodesis Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=311 Year: 2002
Malignant pleural effusions Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=177 Year: 2002
CD8+ lymphocyte subpopulations in pleural fluid are associated with longer survival in patients with malignant pleural effusion (MPE) submitted to thoracoscopic talc pleurodesis Source: Eur Respir J 2002; 20: Suppl. 38, 70s Year: 2002
Difficult pleural effusion management (e.g., chylothorax, trapped lung and rheumatoid effusions) Source: International Congress 2017 – PG5 Pleural disease management Year: 2017
Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients Source: Eur Respir J 2011; 38: 1425-1430 Year: 2011
Talc pleurodesis in malignant pleural effusions: A 5-year experience Source: Annual Congress 2012 - Medical access to the pleura Year: 2012
Efficacy and safety of talc pleurodesis in patients with malignant pleural effusions Source: Eur Respir J 2006; 28: Suppl. 50, 754s Year: 2006
Talc slurry vs bleomycin in treatment of malignant pleural effusions Source: Eur Respir J 2005; 26: Suppl. 49, 448s Year: 2005
Systemic treatment of malignant pleural effusion Source: Annual Congress 2005 - What's new in the pleura Year: 2005
Metastatic pleural effusions (mpes) Source: Annual Congress 2008 - Various aspects of thoracic oncology Year: 2008
Predictors of survival in patients with recurrent malignant pleural effusion Source: Annual Congress 2008 - Diagnostic and therapeutic approaches in pleural diseases Year: 2008
Pleurodesis with erythromycin in large and recurrent malignant pleural effusions Source: Eur Respir J 2005; 26: Suppl. 49, 72s Year: 2005